secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001387131-23-004783
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adamis Pharmaceuticals receives Nasdaq deficiency notice for MVLS below $35M
----------------------------------------------------------------------------

- Nasdaq notice on April 12, 2023: Market Value of Listed Securities below $35M for 30 consecutive business days.
- Company has until Oct 9, 2023 to regain compliance by achieving MVLS >= $35M for 10 consecutive business days.
- If not compliant by deadline, Nasdaq will issue delisting notice; company may appeal.
- No immediate impact on listing or trading of common stock (ADMP).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123004783/0001387131-23-004783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123004783/admp-8k_041223.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-004783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer